| Name | Title | Contact Details |
|---|---|---|
Yuhong Qiu |
VP, Regulatory Affairs | Profile |
Jim Pepin |
General Counsel | Profile |
Marina Biotech`s focus is to treat the intersection of arthritis, pain, hypertension, and oncology diseases using combination therapies of already approved drugs. The company is developing and commercializing late stage, non-addictive pain therapeutics. The company`s `next-generation of celecoxib,` including IT-102 and IT-103, are designed to control the dangerous side-effect of edema that prohibits the drug from being prescribed at higher doses. These have the potential of replacing opioids and combating the opioid epidemic. They are also being developed as anticancer agents against FAP and CRC. On the Sales and Marketing front- we are actively promoting sales and distribution of our FDA approved drug- Prestalia- through our patient centric care program: 1) We have developed a patented total care program which increase compliance to over 80%. 2) Increase compliance is expected to improve care for hypertensive patients, especially resistant hypertensive patients which currently have no treatment available to them. 3) Resistant hypertension market size is large with 22% of all hypertensive pts eventually become resistant hypertension 4) Compliance/counseling has been shown clinically to treated resistant hypertensive patients 5) Deep pipeline a. Perindopril- Hypertension monotherapy. ACEON (Perindopril) NDA b. Prestalia- Hypertension combination therapy. i. Perindopril/Amlodipine, ii. 1st line hypertension, c. Atorvastatin/Perindopril: Hypertension and lipid disorder d. Pipeline drug: Hypertension and Pain. IT-102, IT-103
Proton Laboratories, Inc is a Alameda, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Eurofins is a Des Moines, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We specialize in recruiting clinical research talent and understand the hiring objectives of our Medical Device, Biotechnology, and Pharmaceutical clients.
Personalis, Inc. is partnering with biopharma to develop and commercialize the next generation of cancer immunotherapies. We provide advanced genomic sequencing and analytics for immuno-oncology. Our patented ACE (Accuracy and Content Enhanced) Technology forms the foundation of all Personalis products and makes it possible for us to achieve augmented coverage of difficult-to-sequence genomic regions often missed with the use of conventional sequencing techniques, for more comprehensive and accurate genomic data. ACE ImmunoID, our universal platform for immuno-oncology, combines augmented whole exome and transcriptome assays with analytics that capture neoantigens, elucidate the tumor microenviroment, and identify mechanisms of tumor escape.